Breaking News, Collaborations & Alliances

Cellares, Stanford University Partner to Expand Automated Manufacturing Beyond T Cell Therapies

Establish a platform manufacturing process and analytics designed to support gene-edited hematopoietic stem cell therapies for HIV and more than 19 rare diseases.

Author Image

By: Charlie Sternberg

Associate Editor

Cellares, an Integrated Development and Manufacturing Organization (IDMO), has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and release testing for gene-edited hematopoietic stem cell (HSC) therapies, expanding the application of Cellares’ automation platforms beyond T cell therapies into a new cell modality. Gene-edited HSCs are being developed as durable, potentially one-time ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters